Propel Bio Management, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Propel Bio Management, LLC reported 21 stock positions worth $100.7 million. Its top holding was Plains GP (PAGP) at 23.2% of the portfolio, followed by Madrigal Pharmaceuticals (MDGL, 13.2%) and Akero Therapeutics (AKRO, 9.5%). Compared with Q3 2024, it opened 2 new positions, sold out of 2, added to 4 and reduced 2. The biggest buy was Syndax Pharmaceuticals (SNDX, shares +38%) and the biggest sale an exit from Telesat (TSAT).
- Most Recent 13F
- Q2 2026
- Location
- Los Angeles, CA
- CIK
- 0001969764
- Portfolio Value
- $100.7M (Q4 2024)
- SEC Filing
- 0001829126-25-000973 ↗ filed Feb 14, 2025
Holdings Value
Holdings 21 stocks · $100.7M
| PAGP Plains GP Holdings LP | 23.23% | 1,272,360 | $23.4M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 13.19% | 43,032 | $13.3M | No change |
| AKRO Akero Therapeutics Inc. | 9.50% | 343,729 | $9.6M | No change |
| ACHV Achieve Life Sciences Inc. | 8.58% | 2,453,092 | $8.6M | No change |
| APLT Applied Therapeutics Inc. | 8.18% | 9,615,420 | $8.2M | Add +46.4% |
| PHAT Phathom Pharmaceuticals Inc. | 7.98% | 989,927 | $8.0M | Add +13.8% |
| TCRX Tscan Therapeutics Inc. | 6.30% | 2,087,139 | $6.3M | No change |
| RNAM Avidity Biosciences Inc. | 5.16% | 178,500 | $5.2M | No change |
| ARDX Ardelyx Inc. | 4.79% | 950,947 | $4.8M | Reduce -11.2% |
| ABEO Abeona Therapeutics Inc. | 3.45% | 624,022 | $3.5M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 2.41% | 183,259 | $2.4M | Add +37.5% |
| KYMR Kymera Therapeutics Inc. | 2.25% | 56,359 | $2.3M | No change |
| ZVRA Zevra Therapeutics Inc. | 1.49% | 179,874 | $1.5M | No change |
| KURA Kura Oncology Inc. | 1.12% | 130,000 | $1.1M | No change |
| ATHIRA PHARMA INC | 0.87% | 1,492,792 | $876K | No change |
| EIGRQ Eiger Biopharmaceuticals Inc. | 0.76% | 146,381 | $765K | No change |
| JSPR Jasper Therapeutics Inc. | 0.42% | 20,000 | $428K | New |
| DCTH Delcath Systems Inc. | 0.20% | 17,000 | $205K | New |
| CMPS Compass Pathways PLC | 0.09% | 25,209 | $95K | Reduce -68.5% |
| MATPF Maat Pharma Saca | 0.02% | 3,151 | $25K | Add +31.5% |
| CHINOOK THERAPEUTICS CVR | 0.01% | 79,357 | $10K | No change |
Portfolio Sells Q3 2024 → Q4 2024
Portfolio Buys Q3 2024 → Q4 2024
| SNDX Syndax Pharmaceuticals Inc. | Add +37.5% | 2.41% | +0.92 |
| JSPR Jasper Therapeutics Inc. | New | 0.42% | +0.42 |
| DCTH Delcath Systems Inc. | New | 0.20% | +0.20 |
| MATPF Maat Pharma Saca | Add +31.5% | 0.02% | +0.01 |
| PHAT Phathom Pharmaceuticals Inc. | Add +13.8% | 7.98% | −1.14 |
| APLT Applied Therapeutics Inc. | Add +46.4% | 8.18% | −24.20 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 29 | $191.1M | PAGP, ACHV, CORT, PHAT, DCTH |
| Q1 2026 | 38 | $158.7M | PAGP, ACHV, PHAT, DCTH, CORT |
| Q4 2025 | 20 | $117.1M | PAGP, ACHV, PHAT, VRDN, MIST |
| Q3 2025 | 16 | $99.9M | PAGP, ACHV, AKRO, MIST, APLT |
| Q2 2025 | 16 | $82.4M | PAGP, ACHV, AKRO, PHAT, ABEO |
| Q1 2025 | 18 | $86.1M | PAGP, MDGL, AKRO, PHAT, ACHV |
| Q4 2024 | 21 | $100.7M | PAGP, MDGL, AKRO, ACHV, APLT |
| Q3 2024 | 21 | $172.4M | APLT, PAGP, PHAT, ACHV, TCRX |
| Q2 2024 | 24 | $154.2M | APLT, PAGP, TCRX, MDGL, ACHV |
| Q1 2024 | 28 | $171.8M | APLT, HIGH, TCRX, MDGL, ACHV |